Payment overview · 2025
General Payments
$2,968.50
126 reported records · 22 companies
Healthcare provider profile · identity verified
Cynthia Ulm, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LOS ANGELES, CA · NPI 1710143078
Verified facts
What the public records show
CMS Open Payments records show Cynthia Ulm, NP received $2,968.50 in general payments during 2025 across 126 reported records.
Novo Nordisk Inc accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $436.25 | 14.7% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $436.24 | 14.7% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $354.38 | 11.9% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $268.36 | 9.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $214.67 | 7.2% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $198.17 | 6.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.04 | 4.5% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $130.20 | 4.4% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $115.04 | 3.9% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $95.72 | 3.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $93.33 | 3.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.62 | 2.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.14 | 2.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.31 | 1.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $51.29 | 1.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.69 | 1.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.52 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.62 | 1.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.02 | 0.9% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $27.84 | 0.9% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $26.20 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.85 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,956.94 | 125 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $283.29 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $235.72 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $232.53 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $194.50 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $170.01 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $166.55 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $159.88 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $146.12 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $134.92 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $130.20 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.59 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.48 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $115.04 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $111.07 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $96.01 | 5 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $95.72 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $93.33 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.62 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $76.89 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $76.39 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $70.29 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $51.63 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.69 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.67 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $19.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 61 |
| Gabapentin | Gabapentin | 92 | 45 |
| Omeprazole | Omeprazole | 74 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 25 |
| Metformin Hcl | Metformin Hcl | 73 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 37 |
| Buspirone Hcl | Buspirone Hcl | 70 | 30 |
| Losartan Potassium | Losartan Potassium | 69 | 34 |
| Lisinopril | Lisinopril | 66 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 26 |
| Famotidine | Famotidine | 56 | 29 |
| Ozempic | Semaglutide | 54 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 20 |
| Linzess | Linaclotide | 44 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 18 |
| Ibuprofen | Ibuprofen | 38 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 13 |
| Clotrimazole | Clotrimazole | 35 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 33 | 12 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 22 |
| Montelukast Sodium | Montelukast Sodium | 32 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 20 |
| Alendronate Sodium | Alendronate Sodium | 31 | 15 |
| Eliquis | Apixaban | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 13 |
| Nystatin | Nystatin | 27 | 19 |
| Furosemide | Furosemide | 24 | 12 |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Atenolol | Atenolol | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 16 |
| Jardiance | Empagliflozin | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 13 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Prednisone | Prednisone | 14 | 14 |
| Azithromycin | Azithromycin | 13 | 13 |
| Finasteride | Finasteride | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Carteolol Hcl | Carteolol Hcl | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,968.50 · 126 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ETERNA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, WAKIX, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error